The brief

Analyst view

• Insilico went public on Hong Kong Stock Exchange in late 2025, raising approximately $293 million.
• In March 2026, Insilico signed a $2.75B AI drug discovery agreement with Eli Lilly.
• $106M revenue in H1 2026 (287% YoY growth), with $51M adjusted net profit.

Technical approach

As reported

Biology42

Target discovery and biomolecule optimization

Uses AI to identify disease targets and optimize biologics like antibodies and peptides without relying on animal testing.

Chemistry42

Molecular generation and synthesis planning

Generative AI designs novel small molecules and predicts synthesis routes, accelerating chemistry workflows.

Medicine42

Clinical trial design and prediction

AI predicts clinical outcomes and designs efficient trials to reduce development time and cost.

Science42

Research assistance and sustainability

Supports various research domains and applies AI to sustainability and non-drug discovery problems.

Show all 4